Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · May 27, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment option for patients with metastatic tumors, which are cancers that have spread from their original site to other parts of the body. The study focuses on a new therapy called 177Lu-EB-FAPI, which is designed to target and treat these tumors more effectively. Researchers are trying to understand how well this therapy works and how it is processed in the body. Participants will undergo imaging tests (68Ga-FAPI PET/CT and 18F-FDG PET/CT) to help track the tumors before starting the treatment.

To be eligible for the trial, participants should have confirmed metastatic tumors, whether they have received treatment or not. They must also be between the ages of 65 and 74 and be able to give consent to participate. Pregnant and breastfeeding women, as well as those with certain medical conditions that could interfere with the study, cannot participate. If you join this trial, you can expect to receive a new type of treatment and contribute to important research that may help others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • confirmed treated or untreated metastatic tumors patients;
• • 68Ga-FAPI PET/CT and 18F-FDG PET/CT within two weeks;
• • signed written consent.
• Exclusion Criteria:
• • pregnancy;
• • breastfeeding;
• • any medical condition that in the opinion of the investigator may significantly interfere with study compliance